Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Novus Therapeutics, Inc. on September 28, 2017. The filing details the voting results for director elections and the ratification of the independent auditor. Note: The request metadata references "Eledon Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Novus Therapeutics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1: Election of Class III Directors
- Gregory J. Flesher: 3,684,789 votes For; 3,498 votes Withheld; 494,094 Broker Non-Votes.
- Gary A. Lyons: 3,606,810 votes For; 81,477 votes Withheld; 494,094 Broker Non-Votes.
- Both nominees were elected to serve three-year terms expiring at the 2020 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes: 4,176,922 For; 3,384 Against; 2,075 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the reporting of the voting results.
Investor Verification Checklist
- Verify the correct registrant name (Novus Therapeutics, Inc.) versus the metadata reference (Eledon Pharmaceuticals, Inc.).
- Confirm the successful election of Gregory J. Flesher and Gary A. Lyons to the Board of Directors.
- Confirm the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2017.
- Note the significant number of Broker Non-Votes (494,094) on the director election proposals.